BGP-15 100 mg QD + BGP-15 100 mg BID + Placebo BID + BGP-15 200 mg QD + BGP-15 200 mg BID + BGP-15 400 mg QD
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus
Conditions
Diabetes Mellitus
Trial Timeline
Oct 1, 2010 → Oct 1, 2011
NCT ID
NCT01069965About BGP-15 100 mg QD + BGP-15 100 mg BID + Placebo BID + BGP-15 200 mg QD + BGP-15 200 mg BID + BGP-15 400 mg QD
BGP-15 100 mg QD + BGP-15 100 mg BID + Placebo BID + BGP-15 200 mg QD + BGP-15 200 mg BID + BGP-15 400 mg QD is a phase 2 stage product being developed by Thermo Fisher Scientific for Diabetes Mellitus. The current trial status is terminated. This product is registered under clinical trial identifier NCT01069965. Target conditions include Diabetes Mellitus.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01069965 | Phase 2 | Terminated |
Competing Products
20 competing products in Diabetes Mellitus